Autologous Nanofat Injection: A single session of intradermal injection of autologous nanofat prepared from centrifuged and mechanically emulsified adipose tissue for treatment of post-traumatic atrophic scars.
Fractional CO2 Laser: Fractional ablative carbon dioxide laser (10,600 nm) administered in three sessions at one-month intervals for treatment of post-traumatic atrophic scars.
Study summary
Post-traumatic atrophic scars are characterized by skin depressions caused by loss of collagen and can lead to cosmetic and psychological concerns. Several treatment options have been proposed, including fractional carbon dioxide (CO2) laser resurfacing and autologous nanofat grafting, both of which may improve scar appearance through skin remodeling and regeneration. This prospective comparative study evaluates the safety and efficacy of fractional CO2 laser alone, autologous nanofat injection alone, and combination therapy in patients with post-traumatic atrophic scars. Sixty participants were assigned to one of three treatment groups and were assessed using the Vancouver Scar Scale, physician global assessment, patient satisfaction, dermoscopic examination, and histopathological evaluation. The study aims to determine whether combining fractional CO2 laser and nanofat injection provides superior clinical and regenerative outcomes compared with either treatment alone while maintaining an acceptable safety profile.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Male or female participants aged 12 years or older.
* Presence of post-traumatic atrophic scar(s) of at least 6 months' duration.
* No scar treatment received during the previous 6 months.
* Willingness and ability to provide written informed consent (or assent with -parental/guardian consent for minors, according to local regulations).
* Willingness to comply with study procedures and follow-up assessments.
Exclusion Criteria:
* Hemoglobin \<10 g/dL.
* Active infection or viral skin disease.
* Coagulopathy or hemophilia.
* Current anticoagulant therapy.
* Diabetes mellitus.
* History of keloid formation.
* History of malignancy or prior radiation therapy.
* Immunosuppression.
* Long-term systemic corticosteroid therapy.
* Photosensitivity disorders.
* Pregnancy or breastfeeding.
* Renal or hepatic disease.
* Systemic diseases affecting wound healing.
* Thin patients with insufficient adipose tissue for adipose tissue harvesting.
* Previous scar treatment within the preceding 6 months.
* Use of systemic retinoids within the preceding 6 months. -Use of topical retinoids within the preceding 2 weeks.-
Primary outcome measure(s)
Change in Vancouver Scar Scale Score — Baseline and 3 months after completion of treatment The change in scar severity assessed using the Vancouver Scar Scale (VSS), including vascularity, pigmentation, and pliability, from baseline to the post-treatment assessment.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
